CHICAGO — Biologics are a game changer for the treatment of thyroid eye disease, according to one speaker at the American Academy of Ophthalmology meeting.
“Biologics are monoclonal antibodies targeting a specific antigen and hold the promise of selective disease modification — that’s efficacy with limited side effects,” Rona Z. Silkiss, MD, said.
Rituximab was the first biologic used for thyroid eye disease (TED), described in 2009. Tocilizumab followed shortly after and was approved in 2010 by the FDA for rheumatoid arthritis.
“But the world change in terms